Showing results (1161-1170 of 31,365) with videos related to
Sort By:
Pageof 3,137
Journal of Medicinal Chemistry|January 9, 2004
Discovery of a bulky 2-tert-butyl group containing primaquine analogue that exhibits potent blood-schizontocidal antimalarial activities and complete elimination of methemoglobin toxicityMeenakshi Jain, Suryanarayana Vangapandu, Sandeep Sachdeva, et al.Journal of Medicinal Chemistry|January 23, 2004
Synthesis of nitro esters of prednisolone, new compounds combining pharmacological properties of both glucocorticoids and nitric oxidePier Giovanni Baraldi, Romeo Romagnoli, Maria Del Carmen Nuñez, et al.Journal of Medicinal Chemistry|January 23, 2004
Anti-AIDS agents. 52. Synthesis and anti-HIV activity of hydroxymethyl (3'R,4'R)-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone derivativesLan Xie, Donglei Yu, Carl Wild, et al.Journal of Medicinal Chemistry|February 6, 2004
Synthesis of a 5-methylindolyl-containing macrocycle that displays ultrapotent Grb2 SH2 domain-binding affinityZhen-Dan Shi, Kyeong Lee, Chang-Qing Wei, et al.Journal of Medicinal Chemistry|February 6, 2004
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivativesSong Seok Shin, Youngjoo Byun, Kyung Min Lim, et al.Journal of Medicinal Chemistry|February 6, 2004
Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activityAdele Bolognese, Gaetano Correale, Michele Manfra, et al.Journal of Medicinal Chemistry|February 6, 2004
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-SrcPatrick A Plé, Tim P Green, Laurent F Hennequin, et al.Journal of Medicinal Chemistry|February 6, 2004
Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variantRino Ragno, Antonello Mai, Gianluca Sbardella, et al.Journal of Medicinal Chemistry|February 6, 2004
Ligand-based structural hypotheses for virtual screeningAjay N JainJournal of Medicinal Chemistry|January 23, 2004
Inhibition of the bacterial enoyl reductase FabI by triclosan: a structure-reactivity analysis of FabI inhibition by triclosan analoguesSharada Sivaraman, Todd J Sullivan, Francis Johnson, et al.Pageof 3,137